SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz, Thomas Ruhstaller(University Hospital Bonn), Daniela Bärtschi(Swiss Group For Clinical Cancer Research), Daniel Rauch(Washington University in St. Louis), Kyung-Jae Na(Novartis (Switzerland)), Andreas Wicki(University Hospital of Basel), Andreas Trojan(Immunologie-Zentrum Zürich), Roger von Moos(Kantonsspital Graubünden), Tamara Rordorf(Institut Gustave Roussy), Ursula Hasler-Strub(Kantonsspital Graubünden), Sandro Anchisi(Hôpital du Valais), Khalil Zaman, Richard Cathomas(Kantonsspital Graubünden), Marc Küng(HFR Freiburg Kantonsspital), Klazien Matter‐Walstra(University of Basel), Martin Bigler(Swiss Group For Clinical Cancer Research), Andreas Müller(Kantonsspital Winterthur), Markus Borner(University of Bern), Marcus Vetter(University Hospital of Basel), Jürg Bernhard(International Breast Cancer Study Group)
Cited by 46
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
|European Urology|2020|2.2k